← Back

Wire · opportunities

FDA approves new oral breast cancer drug combo that cut progression risk 62%: 6 notes

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at beckersoncology.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA has approved Roche's Wilserdly (giredestrant) combined with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, showing a 62% reduction in progression risk. This approval follows positive phase 3 evERA trial results and positions Wilserdly as a key oral therapy in this breast cancer subtype, with a pending FDA decision on its adjuvant use.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 16 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

You can capitalise on emerging oral treatments for ESR1-mutated breast cancer as new regulatory approvals open market access. Prioritise partnerships that leverage this novel drug combo to serve patients resisting existing therapies.

◆ Coverage

5 sources · first reported 16 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalbreast-canceroral-drugclinical-trialnext-gen-serd